Nextech Invest Ltd. 13F Portfolio

CIK 1595430 Filing since Q1 2025 Q3 2026 filed Nov 16, 2026
Holdings as of Sep 30, 2026, from the 13F filed Nov 16, 2026.

Portfolio Snapshot

16 positions · Q3 2026

Nextech Invest Ltd. reported 16 positions worth $2.17B for the quarter ended Sep 30, 2026, up 3.0% on the prior quarter. It opened 2 new positions, added to 2, trimmed 1 and exited 1. Its largest holding is Revolution Medicines, Inc. at 71.9% of the portfolio.

Portfolio Value
$2.17B
+3.0% QoQ · +232.4% YoY
Positions
16
2 new · 1 sold out
Top 10 Concentration
98.1%
of portfolio value
Largest Position
RVMD 71.9%
Revolution Medicines, Inc.
Net Buying
+$16.28M
$35.72M bought · $19.44M sold
Turnover
0.9%
of the portfolio traded
Top Sector
Healthcare
100% of value
Track Record
7
quarters on file since Q1 2025

Portfolio Value & Positions

Value Positions

Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.

Sector Allocation

1 sectors
100%
Healthcare
Healthcare100%

Quarterly Buying & Selling

Bought Sold

Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.

Position Changes

How many positions were opened, added to, trimmed or closed each quarter.

Sector Allocation Over Time

Share of reported value in each sector at every quarter end.

HealthcareOther

Largest Buys

Q3 2026
Holding Change Change % Trade Value Weight
AVTX Avalo Therapeutics, Inc. +766.0K – $11.74M 0.541%
BRVE Braveheart Bio, Inc. +416.7K – $8.42M 0.388%
SLN Silence Therapeutics plc +740.7K +77.8% $8.10M 0.852%
ALMS Alumis Inc. +1.01M +28.5% $7.46M 1.55%

Largest Sells

Q3 2026
Holding Change Change % Trade Value Weight
ARVN Arvinas, Inc. -1.12M -100.0% $17.12M Exited
TYRA Tyra Biosciences, Inc. -106.1K -3.0% $2.32M 3.47%

New Positions

Q3 2026
Holding Shares Trade Value Weight
AVTX Avalo Therapeutics, Inc. +766.0K $11.74M 0.541%
BRVE Braveheart Bio, Inc. +416.7K $8.42M 0.388%

Closed Positions

Q3 2026
Holding Shares Sold Trade Value Prior Weight
ARVN Arvinas, Inc. -1.12M $17.12M 0.812%
Holdings · Q3 2026

16 Positions

As ofSep 30, 2026
Value$2.17B
Top 1098.1%
Avg position$135.70M
# Activity
1 more holdings Create a free account to keep reading this institution’s full portfolio.
Showing 1–15 of 16 positions 13F filings on SEC EDGAR

Tip. Select a row to see that position’s full history at Nextech Invest.

About Nextech Invest Ltd.’s 13F Portfolio

What are Nextech Invest Ltd.’s largest holdings?

As of its Q3 2026 13F filing, Nextech Invest Ltd.’s five largest positions were Revolution Medicines, Inc. (RVMD) at 71.9%, Parabilis Medicines, Inc. (PBLS) at 6.9%, Relay Therapeutics, Inc. (RLAY) at 5.6%, Oric Pharmaceuticals, Inc. (ORIC) at 4.4%, Tyra Biosciences, Inc. (TYRA) at 3.5% of the reported portfolio.

How much is Nextech Invest Ltd.’s portfolio worth?

Nextech Invest Ltd. reported a 13F portfolio worth $2.17B across 16 positions for Q3 2026. That is up 3.0% from the previous quarter.

What did Nextech Invest Ltd. buy in Q3 2026?

Its largest purchases by value were Avalo Therapeutics, Inc. ($11.74M), Braveheart Bio, Inc. ($8.42M), Silence Therapeutics plc ($8.10M). It opened 2 new positions.

What did Nextech Invest Ltd. sell in Q3 2026?

Its largest sales by value were Arvinas, Inc. ($17.12M), Tyra Biosciences, Inc. ($2.32M). It exited 1 positions entirely.

Where does this data come from?

From the Form 13F-HR reports Nextech Invest Ltd. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.

Similar-Sized Institutions

by reported 13F value

13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.